刚刚，人类历史上第一次用AI治愈癌症

TL;DR - Moderna and Merck report that their personalized mRNA cancer therapy, intismeran autogene plus Keytruda, met recurrence-free and distant-metastasis-free survival endpoints in a Phase III trial for high-risk melanoma. The result could mark a major clinical milestone for individualized neoantigen therapies, though the article’s claim that AI “cured cancer” overstates the reported findings.

• The global randomized, double-blind trial enrolled 1,137 patients with surgically resected stage IIB–IV melanoma and compared the combination therapy with Keytruda alone.
• The workflow sequences each patient’s tumor and healthy tissue, selects up to 34 tumor-specific neoantigens computationally, and encodes them in a personalized mRNA vaccine.
• The vaccine trains T cells to recognize tumor mutations, while Keytruda removes PD-1-mediated immune inhibition; no new unexpected safety signals were reported.
• Moderna and Merck plan regulatory discussions and are testing the platform in additional solid tumors, including lung, pancreatic, breast, bladder, and kidney cancers.